Chinook Therapeutics Provides Business Update and Reports First Quarter 2021 Financial Results
“During the first quarter of 2021, Chinook made strong progress with its pipeline of programs for kidney diseases, including initiating the phase 3 ALIGN and phase 2 AFFINITY trials of atrasentan, presenting encouraging clinical data from the BION-1301 program and entering into a strategic collaboration with Evotec,” said
- Presented Gd-IgA1 biomarker data in healthy volunteers from Part 1 (single ascending dose) and Part 2 (multiple ascending dose) of the ongoing phase 1b study of BION-1301 at the
ISN World Congress of Nephrology2021, showing dose-dependent and durable reductions in Gd-IgA1 levels following administration of BION-1301.
- Presented data from the BION-1301 phase 1 intravenous to subcutaneous bioavailability study in healthy volunteers at the
ISN World Congress of Nephrology2021, demonstrating our ability to transition to subcutaneous administration of BION-1301 in cohort 2 of the ongoing phase 1b and future studies.
- Enrolled the first patient in the phase 2 AFFINITY basket trial of atrasentan, a highly potent and selective endothelin A receptor (ETA) antagonist (see www.clinicaltrials.gov, identifier NCT04573920). Chinook expects to report data from initial patient cohorts of this study in 2022.
- Enrolled the first patient with IgA nephropathy (IgAN) in the phase 3 ALIGN trial of atrasentan, (see www.clinicaltrials.gov, identifier NCT04573478). Chinook expects to report top-line proteinuria data from this study in 2023 to support potential accelerated approval from the FDA.
- Entered into a strategic collaboration with Evotec to discover and develop novel precision medicine therapies for lupus nephritis, IgAN, polycystic kidney disease (PKD) and other primary glomerular diseases by leveraging the National Unified Renal Translational Research Enterprise (NURTuRE) patient biobank and Evotec’s proprietary PanHunter multi-omics platform.
- Received rare pediatric disease designation from the
U.S. Food and Drug Administration(FDA) for CHK-336, an investigational oral small molecule inhibitor of lactate dehydrogenase A (LDHA), for primary hyperoxaluria (PH).
Anticipated Upcoming Catalysts
- Part 3 of Chinook's phase 1b study of BION-1301 is currently enrolling IgAN patients in an open-label setting, and Chinook expects to present a small subset of interim patient data in an oral presentation at the 58th
ERA-EDTA Congressin June, as well as additional patient data at the ASN Kidney Week 2021 in November.
- CHK-336 is currently in IND-enabling studies and advancing towards an expected IND submission in late 2021 or early 2022 for the treatment of primary hyperoxaluria.
First Quarter 2021 Financial Results
- Cash Position – Cash, cash equivalents and marketable securities totaled
$222.6 millionat March 31, 2021, compared to $250.4 millionat December 31, 2020.
- Revenue – Total revenue increased by
$0.4 millionfor the first quarter of 2021 compared to the same period in 2020 due to revenue recognized related to research and development services provided under the collaboration agreement with Lilly, which was acquired under the merger with Aduro.
- Expenses –
- Research and development expenses were
$25.7 millionfor the first quarter of 2021 compared to $2.8 millionfor the same period in 2020. The increase was primarily due to external clinical and manufacturing expenses related to the atrasentan and BION-1301 clinical programs; higher employee-related costs, including salaries, benefits and stock-based compensation expense associated with hiring staff to build out our clinical and development capabilities; increased spending for consulting and outside services; and higher facilities and other costs. The three months ended March 31, 2021also includes an upfront fee of $3.3 milliondue to Evotech International GmbHunder a research collaboration and license agreement entered into in February 2021.
- General and administrative expenses were
$9.5 millionfor the first quarter of 2021 compared to $1.3 millionfor the same period in 2020. The increase was primarily due to higher employee-related costs, including salaries, benefits and stock-based compensation expense associated with the addition of administrative staff to buildout our public-company infrastructure; higher legal, consulting and outside services costs; and an increase in facilities and other costs.
- Expenses due to change in fair value of contingent consideration and amortization of intangibles were
$2.3 millionfor the first quarter of 2021 compared to nil for the same period in 2020. These non-cash expenses are due to the quarterly revaluation of assets and liabilities related to the merger with Aduro.
- Research and development expenses were
- Net Loss – Net loss for the first quarter of 2021 was
$37.2 millionor $0.88per share compared to net loss of $5.1 millionor $1.25per share for the same period in 2020.
- Cash Used in Operations – For the first quarter ended
March 31, 2021, cash used in operations totaled $28.1 million.
Cautionary Note on Forward-Looking Statements
Certain of the statements made in this press release are forward looking, including those relating to Chinook’s business, future operations, advancement of its product candidates and product pipeline, clinical development of its product candidates, including expectations regarding cash forecasts and timing of initiation and results of clinical trials. In some cases, you can identify these statements by forward-looking words such as “may,” “will,” “continue,” “anticipate,” “intend,” “could,” “project,” “expect” or the negative or plural of these words or similar expressions. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated, including, but not limited to, our ability to develop and commercialize our product candidates, including initiation of clinical trials of our existing product candidates or those developed as part of the Evotec collaboration, whether results of early clinical trials or preclinical studies will be indicative of the results of future trials, our ability to obtain and maintain regulatory approval of our product candidates, our ability to operate in a competitive industry and compete successfully against competitors that may be more advanced or have greater resources than we do, our ability to obtain and adequately protect intellectual property rights for our product candidates and the effects of COVID-19 on our clinical programs and business operations. Many of these risks are described in greater detail in our filings with the
Consolidated Statements of Operations
(In thousands, except per share amounts)
|Three Months Ended March 31,|
|Collaboration and license revenue||$||351||$||-|
|Research and development||25,697||2,818|
|General and administrative||9,543||1,271|
|Change in fair value of contingent consideration||1,839||-|
|Amortization of intangible assets||420||-|
|Total operating expenses||37,499||4,089|
|Loss from operations||(37,148||)||(4,089||)|
|Other expense, net||67||1,060|
|Net loss per share attributable to common stockholders, basic and diluted||$||(0.88||)||$||(1.25||)|
|Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted||42,136||4,104|
Consolidated Balance Sheets
|Cash and cash equivalents||$||168,092||$||187,750|
|Prepaid expenses and other current assets||6,174||6,447|
|Total current assets||226,000||254,081|
|Property and equipment, net||19,860||20,626|
|Operating lease right-of-use assets||54,420||55,673|
|Intangible assets, net||27,277||27,696|
|In process research & development||39,295||39,295|
|Liabilities and Stockholders’ Equity|
|Accrued and other current liabilities||14,486||15,674|
|Operating lease liabilities||3,135||3,045|
|Total current liabilities||24,984||22,809|
|Contingent value right liability||15,589||13,780|
|Contingent consideration related to acquisition||1,830||1,800|
|Deferred tax liabilities||16,377||16,377|
|Operating lease liabilities||37,966||38,709|
|Other long-term liabilities||1,508||905|
|Total liabilities and stockholders’ equity||$||398,773||$||429,002|
Source: Chinook Therapeutics, Inc.